What is the ROE (Return on Equity) of Beigene this year?
The ROE of Beigene this year is -0.27 undefined.
Beigene ROE 2024
Beigene ROE
-0.27
Ticker
6160.HK
ISIN
KYG1146Y1017
WKN
A144EN
In 2024, Beigene's return on equity (ROE) was -0.27, a -40.52% increase from the -0.45 ROE in the previous year.
Beigene Aktienanalyse
What does Beigene do?
Beigene Ltd is a Chinese biotech company that is active in cancer research. It was founded in 2010 by experienced biotech manager John Oyler. The company is now listed on NASDAQ and also has a presence in the United States. Beigene's business model is to develop and distribute innovative cancer treatments. The company utilizes its extensive expertise in molecular and cellular biology as well as clinical development. The goal is to develop therapies that specifically target tumor cells while sparing healthy tissue. This is intended to improve patient survival rates and quality of life. Beigene specializes in the development of cancer treatments, particularly immunotherapies and precision medicine. The latter utilizes targeted attacks against tumor cells at the molecular level to achieve the most focused and effective treatment possible. The company focuses primarily on rare tumor types for which there are currently few or no effective therapies. Beigene is divided into several divisions that focus on different treatment approaches. One important division is immunotherapies, which activate the patient's own immune system against the tumor. Beigene develops antibodies, for example, that recognize and attack specific tumor cells. CAR-T cell therapy is also part of the company's portfolio. In this approach, the patient's T cells are harvested, genetically modified, and multiplied in the laboratory. These T cells are then reintroduced into the patient's body, where they target the tumor specifically. Another division of Beigene is the so-called small molecule drugs. These are chemical compounds that are introduced into the body and specifically attack tumor cells. Beigene develops inhibitors, for example, that inhibit specific enzymes and thus suppress the growth of cancer cells. Beigene has been particularly successful with its drug Zanubrutinib, which is used to treat lymphomas. The drug has achieved excellent results in clinical trials and has already been approved in several countries. Overall, Beigene is an innovative and promising biotech company that specializes in the development of new cancer treatments. The company has a strong expertise in molecular biology and has already achieved promising successes. With its various divisions and products, Beigene covers a wide range of treatment approaches and is likely to play an important role in the fight against cancer in the future. Beigene ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Beigene's Return on Equity (ROE)
Beigene's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Beigene's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Beigene's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Beigene’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Beigene stock
How has the Return on Equity (ROE) of Beigene developed compared to the previous year?
The ROE of Beigene has increased by -40.52% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Beigene?
A high ROE indicates that Beigene generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Beigene?
A low ROE can indicate that Beigene is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Beigene affect the company?
A change in ROE (Return on Equity) of Beigene can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Beigene?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Beigene?
Some factors that can influence Beigene's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Beigene pay?
Over the past 12 months, Beigene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beigene is expected to pay a dividend of 0 USD.
What is the dividend yield of Beigene?
The current dividend yield of Beigene is .
When does Beigene pay dividends?
Beigene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Beigene?
Beigene paid dividends every year for the past 0 years.
What is the dividend of Beigene?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Beigene located?
Beigene is assigned to the 'Health' sector.
Wann musste ich die Aktien von Beigene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Beigene from 9/15/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/15/2024.
When did Beigene pay the last dividend?
The last dividend was paid out on 9/15/2024.
What was the dividend of Beigene in the year 2023?
In the year 2023, Beigene distributed 0 USD as dividends.
In which currency does Beigene pay out the dividend?
The dividends of Beigene are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Beigene
Our stock analysis for Beigene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beigene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
